Dr. Tatia Aprasidze, MD, PhD, is a pediatric neurologist at M. Iashvili Children’s Central Hospital in Tbilisi, Georgia, and Associate Professor at Georgian National University. She is also a visiting lecturer at David Tvildiani Medical University. She earned her PhD in 2023 on childhood arterial ischemic stroke and completed postdoctoral research at the University Children’s Hospital, Inselspital Bern, Switzerland, supported by the Swiss Government Excellence Scholarship and the EAN Fellowship. Her clinical and research expertise includes pediatric stroke, epilepsy, and neurodevelopmental disorders. She has presented at leading international congresses, published widely, and received the Young Investigator Award at the World Stroke Congress in 2018.

Dr. Lucienne Costa-Frossard França, MD, is a Consultant Neurologist at the National Multiple Sclerosis (MS) Reference Center of the Hospital Universitario Ramón y Cajal in Madrid, Spain, and a researcher at the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). She holds a Medical Degree (Licenciatura en Medicina y Cirugía) from the Universidad de Barbacena (Brazil, 1995), where she graduated with distinction (Premio José Bonifacio de Andrade), and completed her Specialization in Neurology at the Hospital Universitario Ramón y Cajal (Spain, 2006). Dr. Costa-Frossard is an established clinician-scientist with a dual profile in clinical neurology and translational neuroimmunology research, focusing on Multiple Sclerosis (MS). She has extensive experience in clinical trial coordination, having served as principal investigator and national coordinator for numerous multicenter trials in Spain on advanced MS treatments, including anti-CD20 therapies (ocrelizumab, ofatumumab, rituximab), S1P modulators, BTK inhibitors, extended-interval natalizumab, and CAR-T cell therapy approaches.

Dr. Maria del Carmen Rubio Osornio is a distinguished Medical Research Scientist and Academic Leader renowned for her contributions to the field of neurophysiology, particularly in the study of epilepsy and neurological disorders. As a recognized National Researcher Level II (SNI II) within Mexico’s National System of Researchers, she has built a career marked by scientific excellence, leadership, and a strong commitment to advancing biomedical knowledge. A native of Mexico, Dr. Rubio Osornio earned her Ph.D. in Biological and Health Sciences from the Universidad Nacional Autónoma Metropolitana (UAM-Xochimilco) in 2011, following a Master’s Degree in Psychobiology and a Bachelor’s Degree in Psychology, both from the Universidad Nacional Autónoma de México (UNAM). Her multidisciplinary academic background has supported a comprehensive approach to understanding the molecular and physiological mechanisms underlying neurological dysfunction. Dr. Rubio Osornio currently serves as Academic Leader in the Department of Neurophysiology at the National Institute of Neurology and Neurosurgery (INNN MVS), where she also holds the position of Medical Research Scientist “D” within Mexico’s Secretary of Health. Her research focuses on neurophysiological characterization and the molecular pathways involved in epilepsy, including the Wnt/β-catenin signaling pathway and electrophysiological alterations in neuronal populations.

Juliet Haarbauer-Krupa, PhD, FACRM, is an accomplished researcher and clinician with 40 years of experience in traumatic brain injury (TBI) across clinical practice, research, and public health domains. She serves as Adjunct Faculty in the Department of Pediatrics at Emory University School of Medicine and previously worked as a Senior Health Scientist at the CDC’s Division of Injury Prevention, where she led and contributed to national TBI surveillance, prevention, and policy efforts.

Her work spans pediatric and adult TBI, rehabilitation program development, longitudinal research studies, and major contributions to CDC’s Report to Congress on the Management of TBI in Children. She has authored numerous peer-reviewed publications and book chapters, and has received prestigious recognitions including the 2025 Robert L. Moody Prize, the BIAA William Fields Caveness Award, and multiple honors for her research, advocacy, and leadership in brain injury rehabilitation.

Kanchon Kumar Bishnu is an AI Research Scientist in the Department of Computer Science at California State University, Los Angeles. His work focuses on advancing intelligent systems through machine learning, health informatics, cybersecurity analytics, and data-driven automation.

He has authored 15+ peer-reviewed publications in leading journals such as IEEE Access, IEEE Open Journal of the Computer Society, Elsevier, MDPI, Springer Nature, and Tech Science Press. His research contributions span AI-driven medical diagnosis for Parkinson’s, Alzheimer’s, diabetes, cardiovascular disease, and skin cancer, as well as cybersecurity and digital forensics, including cryptocurrency fraud detection and threat prediction.

He serves as a certified reviewer for high-impact journals including Elsevier’s Computers & Electrical Engineering, Biomedical Signal Processing and Control, PLOS ONE, and the Journal of Alzheimer’s Disease (IOS Press).

Kanchon is a UK patent holder in computer science innovation and an advocate for open-access and reproducible research, maintaining public GitHub repositories.

Dr. Masoumeh Khalili is a Postdoctoral Researcher at the International Center for Brain Science, Fujita Health University, Toyoake, Japan. She obtained her Ph.D. in Pharmaceutical Sciences from Mazandaran University of Medical Sciences, Iran, where she conducted pioneering studies on the iron-chelating activity of medicinal plants and mushrooms, particularly Cantharellus cibarius. Before joining Fujita Health University, Dr. Khalili served as a Researcher and Vice Chancellor at the Neuroscience Research Center of Golestan University of Medical Sciences in Iran. During this period, she led multiple research projects investigating the antioxidant and neuroprotective properties of natural compounds and their potential therapeutic roles in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Currently, at Fujita Health University, her research focuses on Fetal Alcohol Spectrum Disorders (FASD), studying both molecular and behavioral consequences of prenatal alcohol exposure, as well as transgenic and knockout mouse models related to bipolar disorder mechanisms.

Dr. Mayur Bhimrao Kale is a dedicated researcher and academician in the field of neuropharmacology and pharmaceutical sciences, with a strong focus on understanding the molecular and behavioral underpinnings of neurological and psychiatric disorders. His research expertise lies in neurobehavioral paradigms, mitochondrial dysfunction, neurodevelopmental disorders, and the therapeutic potential of endogenous amines and phytochemicals. He has contributed significantly to advancing knowledge on the role of agmatine, gut–brain axis interactions, and neuroinflammation in the pathophysiology of neurodegenerative and neurodevelopmental conditions. His recent works also extend to exploring biomarkers of aging, sound-based Vedic interventions, and the impact of environmental stressors such as electromagnetic fields on brain development and function. Dr. Kale has authored and co-authored several peer-reviewed articles in reputed international journals, along with book chapters highlighting translational aspects of neuroscience research. He is actively involved in mentoring young researchers and students, fostering innovation through participation in initiatives like the Smart India Hackathon and incubation-driven healthcare product development. In addition to his academic contributions, Dr. Kale is engaged in interdisciplinary collaborations that bridge pharmacology, behavioral neuroscience, and precision medicine. His long-term vision is to contribute toward developing novel therapeutic strategies and non-invasive interventions that can alleviate the burden of neurological disorders and improve quality of life.

Professor Panagiotis Vlamos is a Full Professor at the Ionian University, Greece, where he serves as Chairman of the University Research Center and Director of the Bioinformatics and Human Electrophysiology Laboratory (BiHELab). He is an internationally recognized researcher in bioinformatics, mathematical modeling, and computational neuroscience, with a particular focus on neurodegenerative diseases and personalized medicine. Professor Vlamos has authored more than 200 scientific papers in peer-reviewed journals and conference proceedings, as well as 16 educational books. His research aims to bridge the translational gap from data to models and from models to drug discovery and personalized therapy, developing quantitative deterministic approaches to biological and clinical problems using high-performance computing and advanced mathematical frameworks.